v3.25.1
Revenue - Viatris Agreement (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Collaborative Arrangements and Co-Promote Agreement    
Percentage of profit share 35.00%  
YUPELRI Monotherapy    
Collaborative Arrangements and Co-Promote Agreement    
Percentage of profit share 35.00% 35.00%
Viatris    
Collaborative Arrangements and Co-Promote Agreement    
Percentage of profit share 65.00%  
Maximum potential payments receivable $ 205,000  
Viatris | Success Based Development Regulatory And Sales Milestones    
Collaborative Arrangements and Co-Promote Agreement    
Collaborative arrangement, future development and commercialization milestones 7,500  
Viatris | Sales milestones    
Collaborative Arrangements and Co-Promote Agreement    
Collaborative arrangement, future development and commercialization milestones 37,500  
Viatris | Collaboration revenue    
Collaborative Arrangements and Co-Promote Agreement    
Revenues 15,388 $ 14,503
Viatris | Revefenacin Monotherapy (TD-4208)    
Collaborative Arrangements and Co-Promote Agreement    
Collaborative arrangement, future development and commercialization milestones 52,500  
Viatris | Future potential combination products    
Collaborative Arrangements and Co-Promote Agreement    
Maximum potential payments receivable 45,000  
Collaborative arrangement, future development and commercialization milestones 7,500  
Viatris | YUPELRI Monotherapy    
Collaborative Arrangements and Co-Promote Agreement    
Maximum potential payments receivable 160,000  
Revenues 20,420 $ 19,329
Collaborative arrangement, future development and commercialization milestones 45,000  
Viatris | YUPELRI Monotherapy | Success Based Development Regulatory And Sales Milestones    
Collaborative Arrangements and Co-Promote Agreement    
Maximum potential payments receivable 10,000  
Viatris | YUPELRI Monotherapy | Sales milestones    
Collaborative Arrangements and Co-Promote Agreement    
Maximum potential payments receivable $ 150,000